Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Date:5/21/2013

change rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; including without limitation dupilumab; unforeseen safety issues resulting from the administration of products and product candidates in patients; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
2. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
3. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
4. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
5. NextBio Announces Translational Medicine Partnership with Sanofi
6. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
7. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
8. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
9. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "MEMS Gyroscopes Analog Devices ADIS16136 ... report to their offering. ... tactical grade applications made a lot of progress ... reliability. They are now accepted in high-reliability environments, ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... NANJING, China, April 26, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... company specializing in the development, manufacturing, and marketing of ... that it will report its unaudited financial results for ... May 10, 2011, before the market opens in the ...
... SAN JOSE, Calif., April 25, 2011 SI-BONE, Inc. ... pioneering the use of a minimally invasive surgical (MIS) ... U.S. Food and Drug Administration (FDA) approved a major ... targets the use of iFuse Implant System® for sacroiliac ...
Cached Medicine Technology:Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2FDA Approves Updated, Clarified Indication for Use for iFuse Implant System® 2FDA Approves Updated, Clarified Indication for Use for iFuse Implant System® 3
(Date:12/17/2014)... This prestigious award is given annually ... outstanding and innovative contributions to the physical therapy ... practice physical therapy by the Private Practice Section ... behalf of Performance Physical Therapy, Michelle Collie PT, ... accepted the award at the Private Practice, APTA ...
(Date:12/17/2014)... A group of 127 scientists sent an “open letter” ... a recent statement by the center that was highly critical ... efficacy of all brain exercises. , Signatories to the open ... center’s statement critical of brain exercise companies that overstate their ... case, in a document it had entitled “A Consensus on ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Project Veritas ... recently brought videos of MIT economist and Obamacare architect ... author James O’Keefe conducted the interview, which is being ... that there was intentional mislabeling in the Affordable Care ... the bill: A two-hundred-and-fifty billion dollar per year tax ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... 26, 2012)Bacteria live in a state of perpetual warfare, ... and when pathogen, over their infected host. New research ... the disease cholera, kills off its microbial rivals by ... not for that defense, called the Type 6 secretion ...
... , WEDNESDAY, Feb. 29 (HealthDay News) -- Added sugar in ... calories U.S. children and teens consume, federal health officials report. ... no more than 15 percent of calories from both ... U.S. Centers for Disease Control and Prevention, published online Feb. ...
... , WEDNESDAY, Feb. 29 (HealthDay News) -- Federal laws requiring ... guidance on whether it,s safe or effective for children to ... The Institute of Medicine (IOM) report noted, however, that there,s ... newborns or the long-term effects of drugs on kids generally. ...
... out, there,s hope. In the March 2012 print issue ... from the University of Florida report that a family ... significant role in the regulation of skeletal muscle mass. ... these transcription factors prevents muscle wasting associated with cancer ...
... Neighborhoods of Case Western Reserve University release new ... of the most pressing public health concerns: obesity, ... briefs statistical public health publications group ... diabetes, hypertension awareness and obesity using five years ...
... Exposure to bisphenol A (BPA), a controversial chemical commonly used ... disease later in life, a new study suggests. ... drinks, but also may be exposed through drinking water, dental ... researchers compared BPA levels in 758 people who were initially ...
Cached Medicine News:Health News:Cholera's nano-dagger 2Health News:Cholera's nano-dagger 3Health News:U.S. Kids Still Eat Too Much Added Sugar: CDC 2Health News:U.S. Kids Still Eat Too Much Added Sugar: CDC 3Health News:Efforts to Improve Research on Kids' Drugs Paying Off: Report 2Health News:No workout? No worries: Scientists prevent muscle loss in mice, despite disease and inactivity 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:BPA Exposure May Raise Risk of Heart Disease 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: